Study of Anlotinib in Patients With Differentiated Thyroid

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03170960` - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT02870569` - Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer	Phase 2
Completed	`NCT01876784` - Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer	Phase 3
Completed	`NCT04971473` - Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal	Phase 3
Recruiting	`NCT05078853` - Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma
Recruiting	`NCT04964284` - Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer	Phase 3
Active, not recruiting	`NCT03690388` - A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy	Phase 3
Recruiting	`NCT02638077` - Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China	N/A
Recruiting	`NCT01700699` - Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors	N/A
Completed	`NCT03176485` - Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors	N/A
Recruiting	`NCT04563780` - The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer
Completed	`NCT03191643` - PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer	N/A
Completed	`NCT02278198` - Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123	Phase 1
Active, not recruiting	`NCT04447183` - The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.	Phase 2
Active, not recruiting	`NCT01263951` - Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone	Phase 2
Recruiting	`NCT04940052` - Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer	Phase 3
Recruiting	`NCT04880798` - Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer	N/A
Recruiting	`NCT05789667` - Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer
Recruiting	`NCT05660954` - Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.	Phase 2
Completed	`NCT00295763` - A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.	Phase 3

NCT number	NCT02586337
Study type	Interventional
Source	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact
Status	Active, not recruiting
Phase	Phase 2/Phase 3
Start date	July 2015
Completion date	December 2019

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms